EMEIS 14.070 € (+3,08 %)
AYVENS 11.710 € (-1,60 %)
EXOSENS 60.700 € (+1,93 %)
FDJ UNITED 22.340 € (-0,84 %)
STIF 59.100 € (+0,17 %)
CVC CAPITAL 12.920 € (-0,92 %)
AXA 42.340 € (-0,14 %)
ESSILORLUXOTTICA 175.350 € (-1,27 %)
BNP PARIBAS ACT.A 100.860 € (-0,24 %)
BUREAU VERITAS 26.050 € (-0,61 %)
L'OREAL 376.950 € (-2,72 %)
UBISOFT ENTERTAIN 5.274 € (+4,02 %)
ACCSYS 0.901 € (+2,39 %)
KLEPIERRE 35.460 € (-1,17 %)
AHOLD DEL 34.800 € (+0,81 %)
AIRBUS 190.180 € (-0,92 %)
J.MARTINS,SGPS 17.440 € (+0,29 %)
ASML HOLDING 1 665.200 € (-0,64 %)
INTERPARFUMS 25.700 € (-1,76 %)
BE SEMICONDUCTOR 311.900 € (-1,86 %)
STELLANTIS NV 5.613 € (+0,77 %)
PROSUS 38.560 € (-1,36 %)
CAPGEMINI 89.500 € (+0,56 %)
SARTORIUS STED BIO 164.600 € (-0,54 %)
UMG 18.800 € (+0,53 %)
LVMH 505.700 € (+0,12 %)
ING GROEP N.V. 27.675 € (+0,54 %)
ADYEN 891.600 € (-1,35 %)
SCHNEIDER ELECTRIC 289.250 € (-0,60 %)
RANDSTAD NV 27.130 € (-0,40 %)
PERNOD RICARD 63.440 € (-0,66 %)
IMCD 83.100 € (-0,95 %)
ASR NEDERLAND 65.720 € (+0,18 %)
HERMES INTL 1 736.000 € (-1,53 %)
SANOFI 74.720 € (+1,88 %)
SOCIETE GENERALE 77.890 € (-0,20 %)
PUBLICIS GROUPE SA 89.760 € (+0,63 %)
NN GROUP 74.520 € (+0,59 %)
AIR LIQUIDE 166.680 € (-0,26 %)
DBT 0.056 € (+1,45 %)
COMPAGNIE ODET 1 506.000 € (+3,58 %)
VIVENDI SE 2.212 € (+1,00 %)
UNIBAIL-RODAMCO-WE 98.000 € (-1,47 %)
ENGIE 26.830 € (+0,11 %)
WERELDHAVE 19.660 € (-0,71 %)
TOTALENERGIES 71.500 € (+1,65 %)
TECHNIP ENERGIES 36.080 € (-0,28 %)
AALBERTS NV 40.300 € (-0,25 %)
SHELL PLC 34.700 € (+1,43 %)
CARREFOUR 15.430 € (+0,03 %)
GALP ENERGIA-NOM 18.665 € (+1,91 %)
FLOW TRADERS 25.760 € (+0,47 %)
EDP 4.378 € (-0,39 %)
X-FAB 9.145 € (-7,72 %)
BOLLORE 5.550 € (+2,78 %)
DASSAULT AVIATION 301.200 € (0,00 %)
LEGRAND 150.250 € (-1,31 %)
UNILEVER 50.610 € (-0,49 %)
ORANGE 16.930 € (-0,44 %)
CREDIT AGRICOLE 17.670 € (+0,28 %) |
17/02/2023 13:30
Orogen Royalties Grants Options, RSUs and DSUs to Independent DirectorsVANCOUVER, BC / ACCESSWIRE / February 17, 2023 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") announces that the Board of Directors have authorized a grant of 156,000 Restricted Share Units ("RSUs"), 156,000 Deferred Share Units ("DSUs") and 238,000 Stock Options to independent board members. The grant is pursuant to the Company's Omnibus Equity Incentive Compensation Plan that was approved by shareholders on October 27, 2022, and forms part of part of the independent board's 2023 remuneration. The RSUs awarded will fully vest on the second anniversary of the date of grant. The DSUs awarded will vest 50% each on the third and fourth anniversaries of the grant date and will settle on the termination of service. The Stock Options will have a life of five years and an exercise price of $0.53 and will vest over three years including 25% that will vest immediately followed by 25% on the first, second and third anniversaries from the date of grant. This RSU, DSU, and Stock Option grant is subject to regulatory acceptance of the TSX Venture Exchange. About Orogen Royalties Inc. On Behalf of the Board To find out more about Orogen, please contact Paddy Nicol, President & CEO at 604-248-8648, and Marco LoCascio, Vice President, Corporate Development at 604-248-8648. Visit our website at www.orogenroyalties.com. Orogen Royalties Inc. This news release includes certain statements that may be deemed "forward-looking statements". All statements in this presentation, other than statements of historical facts, that address events or developments that Orogen Royalties Inc. (the "Company") expect to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believe the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Orogen Royalties Inc View source version on accesswire.com: https://www.accesswire.com/739760/Orogen-Royalties-Grants-Options-RSUs-and-DSUs-to-Independent-Directors Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière